Immunogenicity Response of Mus musculus var. Balb/C after Immunization using Flagellin Salmonella typhi Serovar Semarang

<b>Background and Objective:</b> The flagellin of <i>Salmonella typhi</i> is potentially developed as an identifying antigen in a rapid diagnostic test instrument that may be more accurate than conventional serological tests. Therefore, this study aims to analyze the immunogenicity of flagellin <i>S. typhi</i> as the basis for developing a typhoid fever diagnostic. <b>Materials and Methods:</b> Flagellin was isolated from the bacterial culture of <i>S. typhi</i> serovar Semarang and used as the primary antigen for vaccine assembly. Native flagellin antigen was immunized in Balb/C mice with injection doses of 2, 3, 4, 5 and 6 g/100 L in each group (K0-K5), respectively, via intraperitoneal cavity. Blood serum was collected to ELISA based-measurement for IL-6 and TNF-a titers. Then, specific immunoglobulin (Ig) of anti-flagellin was detected using in-house ELISA and western blotting. <b>Results:</b> The findings in this study showed that immunization at the dose of 4-5 g/100 L significantly decreased the IL-6 titer, i.e., 8.33±0.87 pg mL<sup>1</sup>, compared to control. The antibody titer test analysis showed the highest Ig-G anti-flagellin was found in K4 mice after immunization using a dose of 5 g/100 L with an average absorbance of Ig-G reaching 1.19 ±0.32. <b>Conclusion:</b> The results indicated that the flagellin protein of <i>S. typhi</i> serovar Semarang induces adaptive immune responses and produces specific antibodies against flagellin. The immunogenic properties of the flagellin protein of <i>S. typhi</i> serovar Semarang potentially developed as a specific diagnostic marker. Further research may also focus on a beneficial feature of flagellin as a vaccine candidate.

Markers of Systemic Inflammation and Environmental Enteric Dysfunction Are Not Reduced by Zinc or Multivitamins in Tanzanian Infants: A Randomized, Placebo-Controlled Trial

OBJECTIVE

To examine whether daily zinc and/or multivitamin supplementation reduce biomarkers of environmental enteric dysfunction (EED), systemic inflammation, or markers of growth in a sample of infants from Dar es Salaam, Tanzania.

STUDY DESIGN

Subgroup analysis of infants participating in a randomized, double-blind, placebo-controlled trial received daily oral supplementation of zinc, multivitamins, zinc + multivitamins, or placebo for 18 months starting at 6 weeks of age. EED (anti-flagellin and anti-lipopolysaccharide immunoglobulins), systemic inflammation (C-reactive protein and alpha-1-acid glycoprotein), and growth biomarkers (insulin-like growth factor-1 and insulin-like growth factor binding protein-3) were measured via enzyme-linked immunosorbent assay in a subsample of 590 infants at 6 weeks and 6 months of age. EED biomarkers also were measured in 162 infants at 12 months of age.

RESULTS

With the exception of anti-lipopolysaccharide IgG concentrations, which were significantly greater in infants who received multivitamins compared with those who did not (1.41 ± 0.61 vs 1.26 ± 0.65, P = .006), and insulin-like growth factor binding protein-3 concentrations, which were significantly lower in children who received zinc compared with those who did not (981.13 ± 297.59 vs 1019.10 ± 333.01, P = .03), at 6 months of age, we did not observe any significant treatment effects of zinc or multivitamins on EED, systemic inflammation, or growth biomarkers.

CONCLUSIONS

Neither zinc nor multivitamin supplementation ameliorated markers of EED or systemic inflammation during infancy. Other interventions should be prioritized for future trials.

TRIAL REGISTRATION

Clinicaltrials.gov: NCT00421668.